Publication Title: 
Journal of Neurology

BACKGROUND: Memantine, an N-methyl-D-aspartate (NMDA) receptor antagonist, has been shown to be safe and to have beneficial effects on cognition, function, behavior, and global patient status in patients with Alzheimer's disease (AD) in studies lasting 3-6 months. It is approved in the U.S. and Europe for the treatment of moderate to severe AD and is currently under investigation for mild to moderate AD. OBJECTIVE: To evaluate the long-term safety of memantine in patients with mild to moderate AD and to investigate the tolerability of once-daily dose administration.

Ott, Brian R.
Blake, Lesley M.
Kagan, Ethel
Resnick, Malca
Memantine MEM-MD-11AB Study Group
Publication Title: 
Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology

Compounds with anti-glutamatergic properties currently in clinical use for various indications (eg Alzheimer's disease, epilepsy, psychosis, mood disorders) have potential utility as novel treatments for alcoholism. Enhanced sensitivity to certain acute intoxicating effects (ataxia, sedative) of alcohol may be one mechanism by which anti-glutamatergic drugs modulate alcohol use.

Chen, Yi-Chyan
Holmes, Andrew
Publication Title: 
Journal of Psychopharmacology (Oxford, England)

The British Association for Psychopharmacology (BAP) coordinated a meeting of experts to review the evidence on the drug treatment for dementia. The level of evidence (types) was rated using a standard system: Types 1a and 1b (evidence from meta-analysis of randomised controlled trials or at least one controlled trial respectively); types 2a and 2b (one well-designed study or one other type of quasi experimental study respectively); type 3 (non-experimental descriptive studies); and type 4 (expert opinion).

Burns, Alistair
O'Brien, John
BAP Dementia Consensus group
Auriacombe, Sophie
Ballard, Clive
Broich, Karl
Bullock, Roger
Feldman, Howard
Ford, Gary
Knapp, Martin
McCaddon, Andrew
Iliffe, Steve
Jacova, Claudia
Jones, Roy
Lennon, Sean
McKeith, Ian
Orgogozo, Jean-Marc
Purandare, Nitin
Richardson, Mervyn
Ritchie, Craig
Thomas, Alan
Warner, James
Wilcock, Gordon
Wilkinson, David
British Association for Psychopharmacology
Subscribe to RSS - Memantine